Jason Bednar

Stock Analyst at Piper Sandler

(2.13)
# 2,860
Out of 5,180 analysts
202
Total ratings
37.58%
Success rate
-5.25%
Average return

Stocks Rated by Jason Bednar

Alpha Tau Medical
Mar 4, 2026
Downgrades: Neutral
Price Target: $5
Current: $6.55
Upside: -23.66%
ICU Medical
Feb 20, 2026
Maintains: Overweight
Price Target: $172$178
Current: $125.38
Upside: +41.97%
Merit Medical Systems
Feb 18, 2026
Maintains: Overweight
Price Target: $113$106
Current: $68.64
Upside: +54.43%
Becton, Dickinson and Company
Feb 10, 2026
Reiterates: Neutral
Price Target: $205$170
Current: $154.69
Upside: +9.90%
Envista Holdings
Feb 6, 2026
Reiterates: Neutral
Price Target: $21$25
Current: $24.26
Upside: +3.05%
Align Technology
Feb 5, 2026
Maintains: Overweight
Price Target: $200$220
Current: $166.26
Upside: +32.32%
GE HealthCare Technologies
Jan 30, 2026
Maintains: Overweight
Price Target: $91$94
Current: $68.77
Upside: +36.69%
Medline
Jan 12, 2026
Initiates: Overweight
Price Target: $50
Current: $42.62
Upside: +17.32%
Sotera Health Company
Jan 9, 2026
Upgrades: Overweight
Price Target: $17$24
Current: $13.25
Upside: +81.13%
The Cooper Companies
Dec 5, 2025
Reiterates: Overweight
Price Target: $83$94
Current: $69.31
Upside: +35.62%
Maintains: Overweight
Price Target: $94$98
Current: $63.45
Upside: +54.45%
Maintains: Neutral
Price Target: $3.5$4
Current: $4.25
Upside: -5.88%
Maintains: Overweight
Price Target: $200$210
Current: $177.32
Upside: +18.43%
Downgrades: Neutral
Price Target: $9$2.5
Current: $1.18
Upside: +111.86%
Reiterates: Overweight
Price Target: $34
Current: $10.36
Upside: +228.19%
Maintains: Neutral
Price Target: $20$16
Current: $11.20
Upside: +42.86%
Maintains: Overweight
Price Target: $83$77
Current: $72.70
Upside: +5.91%
Maintains: Overweight
Price Target: $5$4.5
Current: $3.62
Upside: +24.31%
Maintains: Overweight
Price Target: $260$265
Current: $219.38
Upside: +20.79%
Maintains: Overweight
Price Target: $8$6
Current: $2.29
Upside: +162.01%
Maintains: Overweight
Price Target: $70$20
Current: $0.67
Upside: +2,874.86%
Maintains: Outperform
Price Target: $310$372
Current: $452.78
Upside: -17.84%